Udaya Kabadi
Geriatric Medicine · Iowa City, IANPI 1770567786
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,235 of the $76,453 with a category attached, or 93.2%. Sanofi-aventis U.S. LLC accounts for 98.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $26,947 and has fallen 99.5% since, to $143 in 2023.
Across 116 payments — averaging $659.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$75K
- Vertex$500
- Takeda Pharmaceuticals U.S.A., Inc.$275
- Abbott$65
- Amgen$40
- Shire North American Group Inc$38
- plus $183 from 8 others
What the payments were for
- Consulting fees$5001%
- Speaking & faculty fees$71,23593%
- Travel & lodging$2,9974%
- Food & beverage$1,7212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 93 | $75,352 |
| Vertex | 1 | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $275 |
| Abbott | 4 | $65 |
| Amgen | 1 | $40 |
| Shire North American Group Inc | 3 | $38 |
| Antares Pharma, Inc. | 2 | $33 |
| AbbVie | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Lexicon Pharmaceuticals, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Insulet Corporation | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$33,481
- SOLIQUA 100/33$26,617
- AMARYL$14,164
- GATTEX$275
How this compares
Too few geriatric medicine providers in Iowato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $54,471 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $18,186 |
| TrulicityDulaglutide | 14 | $15,517 |
| TradjentaLinagliptin | 17 | $12,832 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,353 |
| Hydrocortisone | 13 | $594 |
| Glimepiride | 81 | $506 |
| Levothyroxine Sodium | 38 | $409 |
| Metformin Hcl | 25 | $207 |
| EuthyroxLevothyroxine Sodium | 18 | $148 |
| Atorvastatin Calcium | 28 | $143 |
| Metformin Hcl ErMetformin Hcl | 13 | $75 |
| Spironolactone | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $75,352 | $18,18618 claims |
| Lilly USA, LLCTrulicity | $30 | $15,51714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Iowaon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Iowa City
- John RachowIowa City$14
- Margo SchillingIowa City$0
- Samuel OrvisIowa City$0
- Kayla EhrmanBettendorf$202K
- Robert BenderDes Moines$7K
- Eric PaulsonRed Oak$2K
- Robert ConnerWest Des Moines$339
- Indira InabathiniJohnston$332
- Scott HansonUrbandale$268
- Sripal PadamKeokuk$78
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.